English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

Allogeneic hematopoietic stem cell transplantation (allo-HSCT), including human leukocyte antigen-matched sibling donor transplantation and alternative donor transplantation, remains a curative approach for patients with ALL. In recent years, the advent of targeted therapy and immunotherapy has changed the transplant indications of ALL, which can also be combined with allografting to further improve transplant outcomes, especially for those with refractory or relapsed ALL. In this review, we summarized the current status of allo-HSCT for ALL, mainly focusing on transplant indications, donor selection, conditioning regimens, graft-versus-host disease prophylaxis, incorporation of targeted immunotherapy with allografting, and measurable residual disease-directed intervention for transplant outcome improvement. We also discussed challenges, such as post-HSCT leukemia relapse treatment and new strategies for complication-related mortality, as well as future directions of allo-HSCT for ALL. Allo-HSCT remains one of the curable therapies for ALL in the era of targeted therapy and immunotherapy. Future directions should focus on decreasing relapse mortality and nonrelapse mortality to further improve the outcomes of patients with ALL.

expert review of hematology

Allogeneic hematopoietic stem cell transplantation for acute lymphoblastic leukemia: current status and future directions mainly focusing on a Chinese perspective